Alcon to Acquire LENSAR

Alcon, a provider of ophthalmology-focused medical devices, has struck a deal to acquire LENSAR, a medical technology company focused on laser solutions for the treatment of cataracts. The acquisition includes ALLY Robotic Cataract Laser Treatment System, LENSAR’s proprietary Streamline software technology, and LENSAR legacy laser system, building Alcon’s femtosecond laser-assisted cataract surgery offering.

“By leveraging our global footprint, we have the opportunity to deliver the benefits of advanced femtosecond laser technology to many more surgeons around the world and continue to improve efficiency in cataract surgery,” said David Endicott, CEO of Alcon.

Per the agreement, Alcon will purchase all outstanding shares of LENSAR for $14 per share (amounting to approximately $356 million) with the potential for an additional $2.75 per share, conditioned upon the achievement of 614,000 cumulative procedures with LENSAR’s products between Jan. 1, 2026, and Dec. 31, 2027. The transaction represents a total consideration of up to $430 million.

The transaction is expected to close in mid-to-late 2025, subject to customary closing conditions, including regulatory approval and approval by LENSAR’s stockholders.